Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

Clinical Infectious Diseases

Volumn 40, Issue 10, 2005, Pages 1481-1491

  Weiner, Marc ^a,g   Benator, Debra ^b   Burman, William ^c   Peloquin, Charles A ^d   Khan, Awal ^e   Vernon, Andrew ^e   Jones, Brenda ^f   Silva Trigo, Claudia ^f   Zhao, Zhen ^e   Hodge, Thomas ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c DENVER PUBLIC HEALTH   (United States)

^d NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f Los Angeles Co/Univ of S CA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFABUTIN; RIFAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONCENTRATION PROCESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; RIFABUTIN; RIFAMYCINS; RISK FACTORS; TREATMENT FAILURE; TUBERCULOSIS;

EID: 20944440618     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/429321     Document Type: Article

References (23)

1. Jasmer RM, Seaman CB, Gonazalez LC, et al. Tuberculosis treatment outcomes - directly observed therapy compared with self-administered therapy. Am J Respir Crit Care Med 2004; 170:561-6.
2. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York City, 1993-1994. Clin Infect Dis 1997; 25:1465-7.
3. Sandman L, Schluger NW, Davidow AL, Bonk S. Risk factors for rifampin-monoresistant tuberculosis: a case-control study. Am J Respir Crit Care Med 1999; 159:468-72.
4. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157:1881-4.
5. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353:1843-7.
6. Tuberculosis Trials Consortium. Once-weekly rifapentine and isoniazid versus twice-weekly rifampin and isoniazid in the continuation phase of therapy for drug-susceptible pulmonary tuberculosis; a prospective, randomized clinical trial. Lancet 2002; 360:528-34.
7. Burman W, Benator D, Vernon A, et al. Use of antiretroviral therapy during treatment of active TB with a rifabutin-based regimen: TBTC Study 23 [abstract 136]. Tuberculosis Trials Consortium. 2003. Available at: http://www.retroconference.org/Search_Abstract_2003/AbstractSearch.aspX. Accessed 31 March 2005.
8. Nettles RE, Mazo D, Alwood K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004; 38:731-6.
9. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62.
10. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis 1999; 3:703.
11. Cascorbi I, Roots I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 1999; 9:123-7.
12. Li RC, Narang PK, Pogesi I, Strolin-Benedetti M. A model based assessment of redistribution dependent elimination and bioavailability of rifabutin. Biopharm Drug Dispos 1996; 17:223-36.
13. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentration associated with outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Tuberculosis Trials Consortium. Am J Respir Crit Care Med 2003; 167:1341-7.
14. Weiner M, Burman W, Khan A, et al. The effect of HIV serostatus on isoniazid pharmacokinetics among patients with active tuberculosis [abstract]. Tuberculosis Trials Consortium. Am J Respir Crit Care Med 2004; 169:A260.
15. Jayaram R, Shandil R, Gaonkar S, et al. Isoniazid pharmacokinetics- pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48:2951-7.
16. Mitchison DA. Role of isoniazid in once-weekly rifapentine treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2003; 167:1298-9.
17. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47:2118-24.
18. Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1200 mg during once-weekly continuation-phase therapy. Tuberculosis Trials Consortium. Am J Respir Crit Care Med 2004; 169:1191-7.
19. Li J, Munsiff SS, Driver CR, Sackoff J. Relapse and rifampin resistance in HIV-infected tuberculosis patients treated with rifampin or rifabutin-based regimens, New York City, 1997-2000. Clin Infect Dis 2005 (in press).
20. Benator D, Weiner M, Burman W, et al. Intensive pharmacokinetics of the nelfinavir-rifabutin interaction in patients with HIV-related tuberculosis treated with a twice-weekly rifabutin-based regimen [abstract]. Am J Respir Crit Care Med 2004; 169:A169.
21. Weiner M, Peloquin C, Khan A, et al. Intermittent rifabutin and isoniazid with daily efavirenz in combination with two nucleosides for treatment of HIV infection and tuberculosis disease [abstract 761]. Tuberculosis Trials Consortium. 2004. Available at: http://www.retroconference.org/ Search_Abstract_2004/AbstractSearch.aspX. Accessed 31 March 2005.
22. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-83.
23. Sonnenberg P, Murray J, Glynn JR, et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358:1687-93.